1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Nobel TB, Livschitz J, Xing XX, et al. Surveillance implications of recurrence patterns in early node-negative esophageal adenocarcinoma. Ann Thorac Surg, 2019, 108(6): 1640-1647.
|
3. |
谭黎杰, 黄志良. 食管癌新辅助免疫治疗的现状及未来. 中华消化外科杂志, 2021, 20(6): 635-638.
|
4. |
Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol, 2015, 16(9): 1090-1098.
|
5. |
Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): A phase Ⅲ multicenter, randomized, open-label clinical trial. J Clin Oncol, 2018, 36(27): 2796-2803.
|
6. |
von Döbeln GA, Klevebro F, Jacobsen AB, et al. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: Long-term results of a randomized clinical trial. Dis Esophagus, 2019, 32(2):1-11.
|
7. |
Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stageⅠandⅡesophageal cancer: Final analysis of randomized controlled phase Ⅲ trial FFCD 9901. J Clin Oncol, 2014, 32(23): 2416-2422.
|
8. |
Ajani JA, D'Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2. 2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2019, 17(7): 855-883.
|
9. |
Liu N, Zhou Y, Lee JJ. IPDfromKM: Reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol, 2021, 21(1): 111.
|
10. |
Shim S, Yoon BH, Shin IS, et al. Network meta-analysis: Application and practice using Stata. Epidemiol Health, 2017, 39: e2017047.
|
11. |
Gignoux M, Roussel A, Paillot B, et al. The value of preoperative radiotherapy in esophageal cancer: Results of a study of the E. O. R. T. C. World J Surg, 1987, 11(4): 426-432.
|
12. |
Nygaard K, Hagen S, Hansen HS, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg, 1992, 16(6): 1104-1109.
|
13. |
Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med, 1996, 335(7): 462-467.
|
14. |
Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med, 1997, 337(3): 161-167.
|
15. |
Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: A prospective randomized trial. J Thorac Cardiovasc Surg, 1997, 114(2): 210-217.
|
16. |
Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: Final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer, 2001, 91(11): 2165-2174.
|
17. |
Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol, 2001, 19(2): 305-313.
|
18. |
安丰山, 黄金球, 谢映涛, 等. 食管癌新辅助放化疗的前瞻性临床研究. 中华肿瘤杂志, 2003, 25(4): 376-379.
|
19. |
Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phaseⅢ trial. Lancet Oncol, 2005, 6(9): 659-668.
|
20. |
Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol, 2007, 25(24): 3719-3725.
|
21. |
Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase Ⅲ trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol, 2008, 26(7): 1086-1092.
|
22. |
Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol, 2009, 27(30): 5062-5067.
|
23. |
Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phaseⅡ trial. Eur J Cancer, 2011, 47(3): 354-360.
|
24. |
Boonstra JJ, Kok TC, Wijnhoven BP, et al. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: Long-term results of a randomized controlled trial. BMC Cancer, 2011, 11: 181.
|
25. |
李孝鹏, 丁宁, 白光平, 等. 新辅助放化疗联合手术与单纯手术治疗局部晚期食管癌的疗效比较. 肿瘤防治研究, 2014, 41(5): 464-467.
|
26. |
Klevebro F, Alexandersson von Döbeln G, Wang N, et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol, 2016, 27(4): 660-667.
|
27. |
Stahl M, Walz MK, Riera-Knorrenschild J, et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. Eur J Cancer, 2017, 81: 183-190.
|
28. |
Cao XF, He XT, Ji L, et al. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus, 2009, 22(6): 477-481.
|
29. |
Lv J, Cao XF, Zhu B, et al. Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol, 2010, 16(13): 1649-1654.
|
30. |
周凯, 王伟, 相加庆. 新辅助化放疗联合手术治疗局部晚期食管癌30例. 中国临床研究, 2018, 31(10): 1375-1378.
|
31. |
Wang DB, Zhang X, Han HL, et al. Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: A meta-analysis. Dig Dis Sci, 2012, 57(12): 3226-3233.
|
32. |
杨振宇, 朱泽武, 阿来古哈, 等. 新辅助放化疗结合手术与单纯手术治疗可切除食管癌的系统评价与Meta分析. 中国胸心血管外科临床杂志, 2017, 24(11): 867-879.
|
33. |
van der Wilk BJ, Eyck BM, Lagarde SM, et al. The optimal neoadjuvant treatment of locally advanced esophageal cancer. J Thorac Dis, 2019, 11(Suppl 5): S621-S631.
|
34. |
Sato Y, Motoyama S, Wada Y, et al. Neoadjuvant chemoradiotherapy followed by esophagectomy with three-field lymph node dissection for thoracic esophageal squamous cell carcinoma patients with clinical stage Ⅲ and with supraclavicular lymph node metastasis. Cancers (Basel), 2021, 13(5): 983.
|
35. |
Liang M, Liu Y, Zhang Z, et al. Fusobacterium nucleatum induces MDSCs enrichment via activation the NLRP3 inflammosome in ESCC cells, leading to cisplatin resistance. Ann Med, 2022, 54(1): 989-1003.
|
36. |
Tan JT, Yang Y, Mao NQ, et al. Effect of neoadjuvant chemoradiotherapy on perioperative immune function of patients with locally advanced esophageal cancer. Dis Esophagus, 2017, 30(2): 1-8.
|
37. |
Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol, 2011, 12(7): 681-692.
|
38. |
陈良亮, 陆晶, 饶钰君, 等. 内镜和外科手术治疗T1N0期食管肿瘤安全性和有效性的系统评价与Meta分析. 中国胸心血管外科临床杂志, 2022, 29(2): 158-165.
|
39. |
Ge F, Huo Z, Cai X, et al. Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: A systematic review and meta-analysis. JAMA Netw Open, 2022, 5(11): e2239778.
|
40. |
Wang Z, Shao C, Wang Y, et al. Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis. Int J Surg, 2022, 104: 106767.
|